Genetic Association of rs2237572 Cyclin-Dependent Kinase 6 Gene with Breast Cancer in Iraq

被引:0
|
作者
Dalya Sh. Al-owaidi
Moaed E. Algazally
Alaa Sadeq Alawaad
机构
[1] Babylon University,Department of Clinical Biochemistry, College of Medicine
[2] University of Al-Ameed,Department of Internal Medicine, College of Medicine
[3] University of Babylon,undefined
来源
Indian Journal of Clinical Biochemistry | 2021年 / 36卷
关键词
Breast cancer; Cell cycle; Cyclin D; Cyclin-dependent kinase 6; rs2237572;
D O I
暂无
中图分类号
学科分类号
摘要
This case–control study is aimed to evaluate serum concentration of Cyclin-Dependent Kinase 6 (CDK6) and the genetic association between rs2237572 CDK6 gene and breast cancer (BC) in Iraq. To attain this goal, 80 patients with BC as cases and 80 healthy individuals as controls were included. Further, BC patients were sorted according to the molecular classification into four subtypes of Luminal A, Luminal B, Her2/neu enriched and TPN. Serum concentration of CDK6 enzyme, allelic and genotypic frequencies of rs2237572 CDK6, and the occurrence of BC phenotype and its subtypes in the studied population were investigated. ELISA technique was used to perform the biochemical testing, while the molecular analysis was achieved by real-time PCR, high resolution melting analysis, conventional PCR, as well as sequencing analysis. The results revealed no significant difference in serum concentration of CDK6 enzyme between patients and healthy controls (p > 0.05). Also, no significant differences were shown between BC patients subtypes (p > 0.05). The rs2237572 CDK6 genotypes were associated with the BC and affirmed that allele C was inherited as a recessive risk factor. Moreover, a highly significant difference between patients’ subtypes in the genotypic frequency of rs2237572 (p < 0.01) was noted. Furthermore, the association of rs2237572 genotypes and CDK6 serum concentration in BC patients showed a considered significant difference between C/C and T/T, C/C and T/C and the CDK6 level (p < 0.05). Nevertheless, T/T and T/C did not show any significant difference with the CDK6 level. Hence, it was concluded that the rs2237572 of CDK6 gene is significantly correlated with BC.
引用
收藏
页码:304 / 311
页数:7
相关论文
共 50 条
  • [21] Effect of palliative radiotherapy and cyclin-dependent kinase 4/6 inhibitor on breast cancer cell lines
    Sharaky, Marwa
    El Kiki, Shereen M.
    Effat, Heba
    Mansour, Heba H.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [22] Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer
    Blais, A
    Labrie, Y
    Pouliot, F
    Lachance, Y
    Labrie, C
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (01) : 146 - 153
  • [23] Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data
    Vidula, Neelima
    Rugo, Hope S.
    CLINICAL BREAST CANCER, 2016, 16 (01) : 8 - 17
  • [24] On the rise of cyclin-dependent kinase inhibitors in breast cancer: progress and ongoing challenges
    Makhlin, Igor
    DeMichele, Angela
    BREAST CANCER MANAGEMENT, 2020, 9 (02)
  • [25] Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors
    Gervaso, Lorenzo
    Montero, Alberto J.
    Jia, Xuefei
    Khorana, Alok A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (01) : 162 - 168
  • [26] Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
    Roberts, Patrick J.
    Bisi, John E.
    Strum, Jay C.
    Combest, Austin J.
    Darr, David B.
    Usary, Jerry E.
    Zamboni, William C.
    Wong, Kwok-Kin
    Perou, Charles M.
    Sharpless, Norman E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06): : 476 - 487
  • [27] Genetic association between the cyclin-dependent kinase inhibitor gene p27/Kip1 polymorphism (rs34330) and cancer susceptibility: a meta-analysis
    Cheng, Xiao-Ke
    Wang, Xue-Jun
    Li, Xiao-Dong
    Ren, Xue-Qun
    SCIENTIFIC REPORTS, 2017, 7
  • [28] Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer
    Fradley, Michael G.
    Nguyen, Nam H. K.
    Madnick, David
    Chen, Yiqing
    DeMichele, Angela
    Makhlin, Igor
    Dent, Susan
    Lefebvre, Benedicte
    Carver, Joseph
    Upshaw, Jenica N.
    DeRemer, David
    Ky, Bonnie
    Guha, Avirup
    Gong, Yan
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (12):
  • [29] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer
    Dubianski, Roman
    Jagiello-Gruszfeld, Agnieszka
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2016, 12 (06): : 209 - 214
  • [30] A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
    Zhang, Jialin
    Xu, Xinyu
    Zhou, Yeyue
    Su, Jingyang
    Wang, Jue
    FRONTIERS IN ONCOLOGY, 2025, 15